Trial Profile
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Apr 2023
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms ENDORSE
- Sponsors Biogen
- 15 Apr 2023 Results post hoc pooled analysis from DEFINE, CONFIRM, and ENDORSE evaluating safety and efficacy of DMF in a subgroup of young adults aged 18-29 years, published in the Neurology and Therapy
- 13 Sep 2020 Results presented at the 8th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis
- 11 Sep 2020 According to a Biogen media release, data from this study will be presented during MSVirtual2020, the eighth joint meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS), which will be held virtually September 11-13, 2020.